BioMarin and Ascendis Pharma Finalize Settlement with Royalties on Yuviwel Sales

BioMarin Announces Settlement with Ascendis Pharma

In a significant development in the biotechnology sector, BioMarin Pharmaceutical Inc. has confirmed a strategic settlement with Ascendis Pharma A/S that resolves ongoing patent disputes. This agreement marks a key moment for both companies in their efforts to innovate and provide treatments for genetic conditions.

Overview of the Settlement

On August 30, 2026, BioMarin disclosed that it has entered into a binding agreement with Ascendis, effectively addressing multiple pending patent-related claims worldwide. The settlement is particularly centered around Yuviwel, Ascendis’s treatment aimed at addressing conditions such as achondroplasia. Notably, under the terms of this agreement, Ascendis has committed to pay BioMarin a royalty rate of 20% on the net sales of Yuviwel in the United States, retroactively applicable to its first commercial sale. Additionally, the agreement stipulates a royalty of 18% on net sales within the European Union, Brazil, and South Korea for an extended period until May 2030.

CEO Alexander Hardy expressed optimism about the resolution, highlighting the importance of collaboration between biotechnology firms in fostering long-term innovation. “This outcome incentivizes companies like BioMarin to keep investing in the kind of long-term innovation that is critical to bringing breakthrough treatments to the people who need them,” he stated. This collaborative spirit is crucial for the continued development of more effective therapies for patients suffering from rare genetic disorders.

Implications for Future Innovations

The settlement not only clears the path for royalty earnings but also emphasizes BioMarin’s robust research and development efforts focused on rare genetic conditions. The agreement includes a license that permits BioMarin to use its patented technologies related to Yuviwel for a range of current and future indications, reinforcing its position in the marketplace.

This settlement serves as an acknowledgment of BioMarin's innovative contributions to biotechnology, particularly its pioneering work on C-type natriuretic peptide (CNP) technology, which is part of the foundation for products such as VOXZOGO (vosoritide), another treatment for achondroplasia. This reinforces BioMarin's commitment to advancing medical treatments that specifically target the needs of children with such genetic conditions.

Settlements Across Borders

The breadth of this agreement addresses all existing claims concerning BioMarin's intellectual property, allowing both firms to move beyond the litigation disputes that have characterized their interactions to date. The settlement includes the dismissal of a Section 337 investigation before the U.S. International Trade Commission (ITC) and resolves litigation in various jurisdictions, including Brazil, Denmark, Germany, South Korea, and the Northern District of California.

This comprehensive resolution showcases a willingness among biopharmaceutical companies to engage in dialogue and settle disputes amicably rather than through protracted legal battles, which can stall innovation and delay access to vital medicines.

Looking Forward

With the settlement in place, both BioMarin and Ascendis Pharma are well-positioned to focus on their core missions—developing groundbreaking treatments for patients. BioMarin, with nearly three decades of experience in the field, remains optimistic about the potential for further advancements that can change the lives of those affected by rare genetic disorders.

BioMarin continues to work diligently to expand its pipeline of therapies which aims to harness genetic science for a greater impact on patient health. The company encourages interested parties to stay informed about their developments and ongoing commitment to innovation, underlining the importance of accessibility to treatments for all who need them.

In conclusion, this landmark settlement is not just a resolution of disputes but a reaffirmation of the importance of collaboration in biopharmaceutical innovation. BioMarin's proactive steps signal its dedication to lead in the realm of genetic diseases while ensuring that the needs of patients remain at the forefront of its mission.